Premium
Mazindol in the treatment of narcolepsy
Author(s) -
Parkes J. D.,
Schachter M.
Publication year - 1979
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1979.tb02976.x
Subject(s) - narcolepsy , mazindol , cataplexy , sleep paralysis , methylphenidate , medicine , dextroamphetamine , anesthesia , amphetamine , modafinil , psychology , psychiatry , attention deficit hyperactivity disorder , dopamine
Thirty‐four subjects with the narcoleptic syndrome were treated with mazindol 3‐8 mg daily for 1 year. Treatment caused a sustained improvement in narcolepsy, but had no effect on cataplexy or sleep paralysis. The response to mazindol was excellent in six subjects, good in 14, moderate in 12 and poor in two. No cardiovascular effects, haematological toxicity, tolerance or dependence occurred. Mazindol 6 mg had the same effect on narcolepsy as d‐amphetamine 50 mg, but caused less side effects.